BioArctic AB Class B BRCTF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $35.00
- Day Range
- $31.78–31.78
- 52-Week Range
- $22.87–40.00
- Bid/Ask
- $18.58 / $40.50
- Shares Outstanding
- 88.72M
- Market Cap
- $2.82B
- Volume/Avg
- 250 / 431
Key Statistics
- Price/Earnings (Normalized)
- 125.00
- Price/Sales
- 23.22
- Dividend Yield (Trailing)
- 0.67%
- Dividend Yield (Forward)
- 0.67%
- Total Yield
- 0.67%
Company Profile
BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. Geographically, it derives a majority of its revenue from North America.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 141
- Website
- https://www.bioarctic.se
Valuation
|
Metric
|
BRCTF
|
|---|---|
Price/Earnings (Normalized) | 125.00 |
Price/Book Value | 12.27 |
Price/Sales | 23.22 |
Price/Cash Flow | 143.52 |
Price/Earnings
BRCTF
Financial Strength
|
Metric
|
BRCTF
|
|---|---|
Quick Ratio | 5.12 |
Current Ratio | 6.54 |
Interest Coverage | 16.30 |
Quick Ratio
BRCTF
Profitability
|
Metric
|
BRCTF
|
|---|---|
Return on Assets (Normalized) | 8.66% |
Return on Equity (Normalized) | 10.55% |
Return on Invested Capital (Normalized) | 9.57% |
Return on Assets
BRCTF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|xWd&q# | LOCK|$GR<! | $126B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|&XxD<h | LOCK|k&R? | $81B | |||
| argenx SE ADR
ARGX
| LOCK|#J>%lF> | LOCK|V? | $55B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|><k$<qy | LOCK|#&h#< | $50B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|w&hjJg< | LOCK|?r? | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|n&>?$g! | LOCK|!Slj | $29B | |||
| Incyte Corp
INCY
| LOCK|yRgVp&l | LOCK|H@# | $24B | |||
| Moderna Inc
MRNA
| LOCK|lYwbMmL | LOCK|!d | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|wM#WQj | LOCK|<Y | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|C^sQ#Xh | LOCK|xS< | $17B |
United States